GlassScriptPhysician profile
Ebenezer O Babalola
NPI 1780655175
$3,162.96
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $733 · 2021: $2,034 · 2023: $103 · 2024: $62.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,157.50 | 2020-2021 | |
| Coloplast Corp | $838.15 | 2020-2021 | |
| Astellas Pharma US INC | $367.29 | 2019-2021 | |
| Caldera Medical, INC | $344.18 | 2020-2021 | |
| Abbvie INC. | $132.20 | 2023-2024 | Botox |
| Boston Scientific Corporation | $64.67 | 2019-2023 | Varithena Administration Pack |
| Medtronic USA, INC. | $49.58 | 2019 | |
| Pfizer INC. | $42.13 | 2020-2021 | |
| Zyla Life Sciences, INC. | $32.73 | 2019-2020 | |
| 180 Medical, INC. | $27.50 | 2021 | |
| Allergan, INC. | $25.08 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $16.92 | 2023 | Myfembree |
| Braintree Laboratories, INC. | $14.35 | 2020 | |
| Hologic Sales and Service, LLC | $13.39 | 2021 | |
| Duchesnay USA Incorporated | $12.99 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $12.61 | 2019 | |
| Urovant Sciences INC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebenezer Babalola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.